In accordance with Connecticut Public Act No. 23-171, Astellas is disclosing to prescribing practitioners and pharmacists in Connecticut certain required wholesale acquisition cost (WAC) pricing information for Astellas-marketed legend drugs.

Please choose a product from the list and select “WAC Information” below.

AMBISOME® (amphotericin B)WAC Information
ASTAGRAF XL® (tacrolimus)WAC Information
CRESEMBA® (Isavuconazonium sulfate)WAC Information
IZERVAY™ (avacincaptad pegol intravitreal solution)WAC Information
LEXISCAN® (regadenoson)WAC Information
MYCAMINE® (micafungin)WAC Information
MYRBETRIQ® (mirabegron)WAC Information
PADCEV® (enfortumab vedotin-ejfv)WAC Information
PROGRAF® (tacrolimus) and PROGRAF® GRANULES (tacrolimus for oral suspension)WAC Information
VEOZAHTM (fezolinetant)WAC Information
VESICARE® (solifenacin)WAC Information
XOSPATA® (gilteritinib)WAC Information
XTANDI® (enzalutamide)WAC Information

The pricing information disclosed represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates or reductions in price. The price paid by patients to acquire the products listed is often different than the WAC prices listed, and most patients do not pay WAC. How much a patient will pay will depend on the patient’s insurance coverage. To learn the exact cost of a prescription, patients should contact their health insurance company or preferred pharmacy. Pricing information listed does not imply safety or efficacy of the product.

The prescribing information approved by the U.S. Food and Drug Administration (FDA) guides appropriate use of Astellas medicines. To access approved prescribing information for Astellas-marketed products in the US, visit The intent of this website is only to provide wholesale acquisition price information to prescribing practitioners and pharmacists in Connecticut in accordance with Connecticut law. For more detailed information or healthcare advice, members of the public should consult their healthcare professionals.